Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 25 Burlington Mall Road, Suite 203 BURLINGTON MA 01803 |
Tel: | 1-781-3016706 |
Website: | https://www.scpharmaceuticals.com |
IR: | See website |
Key People | ||
John H. Tucker President, Chief Executive Officer, Director | Rachael Nokes Chief Financial Officer |
Business Overview |
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay's pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home. |
Financial Overview |
For the fiscal year ended 31 December 2023, Scpharmaceuticals Inc revenues increased from $0K to $13.6M. Net loss increased 49% to $54.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 53% to $55.4M. |
Employees: | 135 as of Mar 12, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $125.40M as of Dec 31, 2023 |
Annual revenue (TTM): | $13.59M as of Dec 31, 2023 |
EBITDA (TTM): | -$55.37M as of Dec 31, 2023 |
Net annual income (TTM): | -$54.81M as of Dec 31, 2023 |
Free cash flow (TTM): | -$59.28M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 36,054,409 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |